CLL / SLL
Clinical trials for CLL / SLL explained in plain language.
Never miss a new study
Get alerted when new CLL / SLL trials appear
Sign up with your email to follow new studies for CLL / SLL, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
Genom att skicka in godkänner du våra Användarvillkor
-
New drug rocbrutinib takes on pirtobrutinib in blood cancer showdown
Disease control Recruiting nowThis study tests a new drug, rocbrutinib, against another drug, pirtobrutinib, in people with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL) whose cancer has returned or stopped responding to treatment. All participants have already tried a type of BTK inh…
Matched conditions: CLL / SLL
Phase 3 • Sponsor: Newave Pharmaceutical Inc • Aim: Disease control
Last updated Aug 13, 2026 00:00 UTC
-
New pill ZE50-0134 takes on Hard-to-Treat leukemia and lymphoma
Disease control Recruiting nowThis early-stage study is testing a new oral drug called ZE50-0134 in 66 adults with chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), or certain low-grade lymphomas that have come back or not responded to prior treatments. The main goal is to check the drug's…
Matched conditions: CLL / SLL
Phase 1 • Sponsor: Lomond Therapeutics Holdings, Inc. • Aim: Disease control
Last updated Aug 02, 2026 00:00 UTC
-
Can a Chemo-Free pill combo outsmart leukemia at first diagnosis?
Disease control Recruiting nowThis phase 3 trial is testing whether a combination of two targeted oral drugs—lisaftoclax and acalabrutinib—can work better than standard chemoimmunotherapy for people newly diagnosed with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL). About 344 particip…
Matched conditions: CLL / SLL
Phase 3 • Sponsor: Ascentage Pharma Group Inc. • Aim: Disease control
Last updated Jul 30, 2026 00:00 UTC
-
New combo therapy aims to outsmart resistant blood cancer
Disease control Recruiting nowThis Phase 3 trial is testing whether adding a new drug called lisaftoclax to a standard BTK inhibitor works better than the BTK inhibitor alone for people with CLL or SLL whose cancer has come back or not responded well to prior BTK inhibitor treatment. About 400 participants wi…
Matched conditions: CLL / SLL
Phase 3 • Sponsor: Ascentage Pharma Group Inc. • Aim: Disease control
Last updated Jun 27, 2026 14:00 UTC
-
New pill takes on tough blood cancers in early trial
Disease control Recruiting nowThis early-phase study is testing an experimental oral drug called LP-168 in about 60 people with several types of B-cell blood cancers that have come back or not responded to prior treatments. The main goals are to find the safest dose and to see how the drug behaves in the body…
Matched conditions: CLL / SLL
Phase 1 • Sponsor: Newave Pharmaceutical Inc • Aim: Disease control
Last updated Jun 27, 2026 09:04 UTC
-
Second chance: new combo targets relapsed CLL after venetoclax fails
Disease control Recruiting nowThis Phase 2 trial tests a combination of two drugs, venetoclax and acalabrutinib, in 60 adults with chronic lymphocytic leukemia (CLL) whose cancer returned after initial treatment with venetoclax plus an antibody. Participants first take acalabrutinib alone for 2 cycles, then a…
Matched conditions: CLL / SLL
Phase 2 • Sponsor: Stichting Hemato-Oncologie voor Volwassenen Nederland • Aim: Disease control
Last updated Jun 27, 2026 08:09 UTC
-
New combo therapy aims to wipe out hidden leukemia cells
Disease control Recruiting nowThis study tests whether adding the drug epcoritamab after standard treatment can make chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL) disappear more completely. About 22 adults who have already received at least 12 months of a BTK inhibitor (acalabrutinib …
Matched conditions: CLL / SLL
Phase 2 • Sponsor: Zulfa Omer • Aim: Disease control
Last updated Jun 27, 2026 08:08 UTC